Pharmacokinetic/pharmacodynamic/(PK/PD) model for abciximab in healthy subjects.

被引：0
|
作者：
Abernethy, DR
Pezzullo, J
Freedman, J
Mascelli, MA
Frederick, B
机构：
[1] Centocor Inc, Malvern, PA 19355 USA
[2] Georgetown Univ, Div Clin Pharmacol, Washington, DC 20007 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2000年 / 67卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
OIIB3
引用
收藏
页码：141 / 141
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetic/pharmacodynamic (PK/PD) model for tolvaptan (TOL) in healthy subjects.
    Van Wart, SA
    Cirincione, BB
    Ludwig, EA
    Chen, X
    Shoaf, S
    Grasela, TH
    Mallikaarjun, S
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P60 - P60
  • [2] POPULATION PHARMACOKINETIC (PK) AND PHARMACOKINETIC-PHARMACODYNAMIC (PK/PD) ASSESSMENT OF GDC-0334 (A TRPA1 INHIBITOR) IN HEALTHY SUBJECTS.
    Chan, H.
    Li, H.
    Liu, L.
    Ding, H.
    Ferl, G.
    Bauer, R.
    Gao, S.
    Joseph, V.
    Yang, X.
    Quartino, A.
    Putnam, W.
    Pan, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S98 - S98
  • [3] POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELING FOR AN ANTISENSE OLIGONUCLEOTIDE (ISIS-FXIRx), TARGETING FACTOR XI, IN HEALTHY SUBJECTS.
    Yu, R.
    Luu, K.
    Bethune, C.
    Bhanot, S.
    Liu, Q.
    Wang, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S81 - S82
  • [4] PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTION OF DRONEDARONE AND NISOLDIPINE IN HEALTHY SUBJECTS.
    Bonnet, Denis
    Sultan, Eric
    Allison, Mark
    Levene, Francoise
    Alberini, Helene
    Gaud, Christine
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09): : 1082 - 1082
  • [5] Pharmacokinetic and pharmacodynamic interaction of eszopiclone and paroxetine in healthy subjects.
    Skolly, SM
    Niewoehner, J
    Maier, G
    PHARMACOTHERAPY, 2004, 24 (10): : 1422 - 1422
  • [6] Pharmacokinetic and pharmacodynamic interaction of eszopiclone and lorazepam in healthy subjects.
    Niewoehner, J
    Anderson, AJ
    Maier, G
    PHARMACOTHERAPY, 2004, 24 (10): : 1421 - 1421
  • [7] Development and evaluation of a population pharmacokinetic (PK) model for darbepoetin alfa in healthy subjects.
    Kuebler, P
    Lu, J
    Xu, L
    Holmgren, E
    Hambleton, J
    Spyker, D
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P76 - P76
  • [8] Pharmacokinetics (PK) and pharmacodynamics (PD) of lanoteplase in healthy subjects.
    Vachharajani, N
    Shyu, W
    Stouffer, B
    Raymond, R
    Liao, W
    Tay, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 180 - 180
  • [9] POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELING OF DEPOT TESTOSTERONE CYPIONATE IN HEALTHY MALE SUBJECTS
    Bi, Y.
    Murry, D.
    Ellerby, M.
    Perry, P. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S80 - S81
  • [10] A new pharmacokinetic/pharmacodynamic model (PK/PD) for mivacurium
    Laurin, J
    Nekka, F
    Donati, F
    Varin, F
    ANESTHESIOLOGY, 1996, 85 (3A) : A323 - A323
12345